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Abstract
Objective: To determine whether the NAD+ biosynthetic protein, nicotinamide
mononucleotide adenylyltransferase-3 (NMNAT3), is a neuroprotective induci-
ble enzyme capable of decreasing cerebral injury after neonatal hypoxia-ische-
mia (H-I) and reducing glutamate receptor-mediated excitotoxic
neurodegeneration of immature neurons. Methods: Using NMNAT3-overex-
pressing mice we investigated whether increases in brain NMNAT3 reduced
cerebral tissue loss following H-I. We then employed biochemical methods
from injured neonatal brains to examine the inducibility of NMNAT3 and the
mechanism of NMNAT3-dependent neuroprotection. Using AAV8-mediated
vectors for in vitro neuronal NMNAT3 knockdown, we then examine the
endogenous role of this protein on immature neuronal survival prior and fol-
lowing NMDA receptor-mediated excitotoxicity. Results: NMNAT3 mRNA and
protein levels increased after neonatal H-I. In addition, NMNAT3 overexpres-
sion decreased cortical and hippocampal tissue loss 7 days following injury. We
further show that the NMNAT3 neuroprotective mechanism involves a decrease
in calpastatin degradation, and a decrease in caspase-3 activity and
calpain-mediated cleavage. Conversely, NMNAT3 knockdown of cortical and
hippocampal neurons in vitro caused neuronal degeneration and increased exci-
totoxic cell death. The neurodegenerative effects of NMNAT3 knockdown were
counteracted by exogenous upregulation of NMNAT3. Conclusions: Our obser-
vations provide new insights into the neuroprotective mechanisms of NMNATs
in the injured developing brain, adding NMNAT3 as an important neuropro-
tective enzyme in neonatal H-I via inhibition of apoptotic and necrotic neu-
rodegeneration. Interestingly, we find that endogenous NMNAT3 is an
inducible protein important for maintaining the survival of immature neurons.
Future studies aimed at uncovering the mechanisms of NMNAT3 upregulation
and neuroprotection may offer new therapies against the effects of hypoxic-
ischemic encephalopathy.
Introduction
Neonatal cerebral hypoxia-ischemia (H-I) is an often dev-
astating condition constituting a significant cause of new-
born death, and chronic neurological and
neurodevelopmental disability in children.1 Despite its rela-
tively high incidence among newborns with cerebral injury,
limited therapies are available for its prevention and
treatment.2,3 Furthermore, unlike the aging adult brain,
neuronal death in the immature CNS is not only a patho-
logical cellular event of brain injury but also a biological
process required for early normal brain development.4
Therefore, understanding the cellular mechanisms that
actively modulate neuronal survival in the neonatal brain
may help better understand the cellular pathways that regu-
late the cell fate of developing neurons as well as provide
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potential new approaches for the treatment of H-I in new-
borns.
The mammalian family of NAD+ metabolizing
enzymes, nicotinamide mononucleotide adenylyltrans-
ferases (NMNATs), may play an important role in the
regulation of neuronal survival during brain development,
and their neuroprotective actions could offer new targets
against the effects of neonatal H-I. NMNATs are potent
inhibitors of axonal degeneration in the peripheral ner-
vous system, they consist of three structurally distinct iso-
forms differentially expressed in all tissues, including
brain, and each localized to different cellular compart-
ments.5–8 Although the neuroprotective actions of
NMNATs in the mammalian brain remain largely unex-
plored, recent evidence suggests that NMNATs are also
strongly protective against axonal and neuronal CNS
degeneration. For example, increases in the expression of
NMNAT1 and NMNAT3 decrease mouse retinal ganglion
cell degeneration following ischemia,9,10 and overexpres-
sion of cytoplasmic NMNAT1 protects the term-equiva-
lent neonatal mouse brain against the degenerative effects
of cerebral H-I via inhibition of glutamate-dependent
excitotoxic cell injury.11 In contrast, depletion of
NMNAT2, the NMNAT isoform most abundant in the
brain, restricts the outgrowth of retinal and cortical fibers
in vitro.12 Interestingly, mutations in NMNAT1 have been
recently identified as a cause of Leber congenital amauro-
sis, a degenerative disease of the young human retina,13
and genome-wide and linkage analysis have demonstrated
an association between NMNAT3 and late-onset Alzhei-
mer’s disease.14
The above observations suggest that all three NMNAT
isoforms are likely important for the survival of both,
peripheral axons and CNS neurons and their processes.
Nevertheless, the neuroprotective role of each of these
proteins following neonatal H-I remains poorly under-
stood. In this study, we used NMNAT3-overexpressing
mice and AAV8 vectors to manipulate NMNAT3 endoge-
nous and exogenous expression in order to examine
whether NMNAT3 protects the immature brain from the
degenerative effects of neonatal cerebral injury. We find
that alterations in the expression of neuronal NMNAT3
in vivo and in vitro significantly modify the survival of
healthy and injured immature neurons possibly via inhi-
bition of glutamate-dependent excitotoxic degeneration
involving the calpastatin/caspase/calpain-mediated death
pathway. These data suggest that NMNAT3 is important
for the survival of developing healthy and injured neu-
rons following neonatal H-I. Investigating the neuropro-
tective actions of NMNAT3 in the ischemic immature
brain may offer new putative cellular targets for the pre-
vention and treatment of perinatal brain injury, and may
also provide new insights into the cellular mechanisms
that modulate cell death in the healthy and injured
developing brain.
Methods
Animals and surgical procedures
Mice overexpressing the mouse NMNAT3 gene
(B6J.B6D2-Tg; CAG-Nmnat3; line #819) under the con-
trol of the chicken b-actin promoter on a C57BL/6 back-
ground were derived from sperm obtained from RIKEN
(Saitama, Japan) as previously described15. To produce
NMNAT3 and wild-type littermate pups for the H-I
experiments, NMNAT3 mice on a C57BL/6 background
were bred to C57BL/6 nontransgenic, wild-type, mice
(Charles Rivers Labs, New York). Genotyping was
performed by PCR on genomic DNA from the toes of
animals using the following primers: NMNAT3-Tg, 50-
GACCGGCGGCTCTAGAGCCTCTGCTAA-30 and 50-GCT
CAAGGGGCTTCATGATGTCCCCATA-30. Animal care
and use in our laboratory were in strict accordance with
the National Institute of Health guidelines on the use of
laboratory animals. All procedures were also approved by
the animal studies committee at Washington University.
Neonatal hypoxic-ischemic brain injury was performed
on postnatal day 7 mice pups as previously described16.
Only pups with a body weight greater than 3.0 g at time
of surgery (P7) were used in this study. Briefly, pups were
anesthetized using 3% halothane for induction and 2.5%
halothane for maintenance (balance room air). Under
anesthesia, blood flow through the left carotid artery was
permanently interrupted by carotid artery cauterization
through an incision in the neck. The pups were returned
to the dam and allowed to recover for a minimum of 3 h
before being placed at 36.5°C in a thermoregulated
hypoxia chamber containing 8% oxygen (balanced with
nitrogen) for a period of 15 or 45 min. After completion
of H-I, pups were returned to the dam until the day they
were euthanized.
Histology and determination of tissue loss
At 7 days following HI, P14 mice pups were deeply anes-
thetized with pentobarbital (150 mg/kg) and perfused
transcardially with ice-cold PBS containing 3 U/mL hep-
arin. Brains were removed and immersion fixed in 4%
(w/v) paraformaldehyde in 0.1 mol/L phosphate buffer
(pH 7.4) at 4°C for 24 h, and then cryoprotected in 30%
(w/v) sucrose in 0.1 mol/L phosphate buffer until freezing
in powdered dry ice and sectioned into 50 lm coronal
sections with a freezing sliding microtome. The unin-
jured, contralateral hemisphere was noted before section-
ing by nicking that hemisphere with a razor blade. A set
ª 2017 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 723
R. Galindo et al. NMNAT3 and Neonatal Cerebral Hypoxia-Ischemia
of coronal brain sections (spaced 50 lmol/L apart) begin-
ning at the genu of the corpus extending to the mid body
of the dorsal hippocampus were mounted in DAPI
mounting medium (Vector Labs) and imaged via Nano-
zoomer (Hamamatsu Photonics). Percent tissue loss was
calculated by comparing areas of distinct brain regions
(cortex, striatum, and hippocampus) in the injured hemi-
sphere (left) and uninjured hemisphere (right) using the
Nanozoomer imaging software as previously
described.11,17 Three coronal sections per quantification
area per animal were used for each of the brain regions
studied. Striatal volume was calculated using those sec-
tions containing the striatum at the level of the genu of
the corpus callosum. Hippocampal injury was determined
by analyzing sections containing all layers of the dorsal
hippocampal formation as seen in Figure 3C. Cortical
areas were analyzed on the sections that contained the
dorsal hippocampus. The investigators were blinded to
the genotype during area analysis.
Immunohistochemistry and
immunofluorescence
To evaluate the localization of NMNAT3 in the brain,
pup brain tissue was sectioned as previously described.
Brain sections were processed for DAB- or fluorescent-
based immunohistochemistry utilizing the free-floating
method. Primary antibodies used were NMNAT3 (1:200,
Santa Cruz), NF200 (1:500, Millipore), and NeuN Alexa
Fluor488 conjugate (1:100, Millipore). Antigen retrieval
was undertaken in 1 mg/mL pepsin in 0.2 mol/L HCl at
37°C for 10 min. Endogenous peroxidases were blocked
with 0.3% H2O2 diluted in TBS (DAB-IHC only), and
proteins were blocked using 3% dried milk in Tris-buf-
fered saline and 0.25% (vol/vol) Triton-X (TBS-X). Brain
sections were incubated with primary antibodies in dilut-
ing buffer (1% dried milk in TBS-X) overnight at 4°C,
followed by incubation in fluorescent-tagged secondary
antibodies Alexa Fluor 488 donkey anti-mouse or Alexa
Fluor 568 donkey anti-goat (1:500, Life Technologies) or
biotinylated donkey anti-goat secondary antibody (1:500,
Jackson Immunoresearch Lab) followed by a final incuba-
tion in avidin-biotin-horseradish peroxidase solution
(Vectastain Elite ABC kit; Vector Laboratories). Detection
of the bright-field immunohistochemical sections was
achieved using 3,30-diaminobenzidine (DAB) chromogen
(Sigma).
Caspase-3 activity assay
At 24 h following the end of H-I, mice pups were sacri-
ficed by rapid decapitation. Brains were extracted and the
left and right hippocampi dissected and frozen using dry
ice. Each hippocampus was homogenized in lysis buffer
(50 mmol/L HEPES, 5 mmol/L DTT, 0.1 mmol/L EDTA,
0.1% CHAPS, pH 7.4) and centrifuged at 10,000 x g for
15 min at 4°C. Tissue lysates incubated in a 96-well plate
with 40 lL of assay buffer (100 mmol/L NaCl, 50 mmol/
L HEPES, 10 mmol/L DTT, 1 mmol/L EDTA, 10% glyc-
erol, 0.1% CHAPS, pH 7.4) containing 30 lmol/L of the
substrate Ac-DEVD-AMC using a Caspase-3 Activity
Assay Kit according to the manufacturer’s instructions
(Calbiochem/Millipore). The emitted fluorescence was
measured every 10 min for 120 min at 37°C at an excita-
tion wavelength of 360 nm and an emission wavelength
of 460 nm using a fluorescent microplate reader (Bio-Tek
Instruments). Protein concentration of each hippocampal
lysate was determined by Bradford Protein Assay (Bio-
Rad). DEVD-AMC cleavage activity was obtained from
the slope by plotting fluorescence units against time. The
enzyme activity was calculated as pico moles of AMC
generated per milligram of protein per minute.
Western blotting
Hippocampal lysates prepared as described above for the
caspase assay were subjected to Western blotting after the
addition of protease inhibitors (Roche). For high-molecu-
lar-weight proteins, samples were resolved on 8–16%
Tris-Glycine gels; for low-molecular-weight proteins, sam-
ples were resolved on 4–12% Bis-Tris NuPage gels (Invit-
rogen). Proteins (20 lg/lane) were separated by SDS-
PAGE and transferred to nitrocellulose membranes using
an iBlot (Life Technologies). Blots were blocked with 5%
dried milk in TBS containing 0.05% Tween-20 overnight
at 4°C. Blots were then incubated for 3 h at room tem-
perature in primary antibody: NMNAT3 (1:200, Santa
Cruz), Calpastatin (1:1000, CST), Alpha-spectrin (1:500,
Millipore), or Beta-actin (1: 50,000, Sigma). Membranes
were then incubated with the appropriate HRP-labeled
secondary antibody (1:2000, Santa Cruz), developed using
either SuperSignal West Pico (Pierce) or ECL Ultra
(Lumigen), and visualized on an ImageStation (Syngene).
The resulting blot images were quantified using ImageJ
software.18
Hippocampal and cortical neuronal cell
culture and excitotoxicity assay
The cortex and hippocampus were microdissected from
embryonic day 18 C57BL/6 embryos incubated in Hank’s
balanced salt solution with 2.5% (10x) trypsin for 7 min
at 37°C. Cortices and hippocampi were gently triturated,
diluted in neurobasal media seeded in 24-well plates pre-
coated with poly-L-Lysine. To avoid plating neurons at
different densities in different wells and to allow for the
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quantification of LDH activity and MAP2 immunofluo-
rescence in the same well, cells were plated at the same
time from a common dissociated neuronal preparation at
a calculated equal neuronal concentration of 100,000
cells/well; all neurons were treated equally to all the con-
ditions except the dependent variable of viral exposure
status. Cells were maintained in neurobasal media plus
1X B-27 supplement, 0.5 mmol/L L-glutamine with peni-
cillin-streptomycin, and 50% of the media was replaced
every 3 days. At DIV12 cultured neurons were washed
with a controlled salt solution (CSS) containing in
mmol/L: 120 NaCl, 5.4 KCl, 1.2 CaCl2, 15 glucose, and
25 Tris-HCl, pH = 7.40, at room temperature. Magne-
sium was omitted to avoid blockade of the NMDA recep-
tor channel. Cells were then exposed to 50 lmol/L
Ibotenic acid with 100 lmol/L glycine in CSS or CSS
alone for 5 min then washed an incubated in neurobasal
media for 24 h prior to cytological assessment by
immunofluorescence and LDH quantification as previ-
ously described.19
In vitro immunofluorescence quantification
Quantification of neurites was achieved by staining PFA-
fixed cortical and hippocampal neurons with a mouse
MAP2 antibody (1:1000, Millipore). Sample digital
images of MAP2 stained neurons of a fixed area were
obtained from the same location in the 24-well plate of
control or experimental cultures blindly and the amount
of immunofluorescence was quantified utilizing ImageJ
analysis software.18 Data were expressed as the amount
of MAP2 stain per unit area. A single N value represents
average stain quantified per area per a single culture
well.
Lactate dehydrogenase assay
At 24 h postexcitotoxic injury with Ibotenic acid or
prior to paraformaldehyde fixation, the media of corti-
cal and hippocampal neuron cultures were collected
and assayed for lactate dehydrogenase (LDH) using a
cytotoxicity detection kit (Roche) as previously
described.11 Briefly, 100 lL of culture medium per well/
sample in duplicate was incubated with gentle shaking
with the kit reagents for 30 min in the dark, after
which the product was measured at 490 nm utilizing a
standard 96-well microplate reader (Bio-Tek Instru-
ments). Following collection of conditioned media for
LDH, cells were fixed with 4% paraformaldehyde in
phosphate buffer for 30 min at room temperature. After
washing with PBS, cells were permeabilized with PBS-X,
blocked in normal serum, and probed for immunocyto-
chemistry.
Real-time qPCR analysis
Real-time qPCR was used for mRNA quantitation of dis-
sociated culture neurons or the microdissected hippocam-
pus and cerebral cortex. At 1 day, 3 days, and 7 days
post-H-I pups were sacrificed by lethal injection of pento-
barbital (150 mg/kg) and decapitated. The right and left
hemispheres were separated, and hippocampal and corti-
cal tissue were dissected out. RNA was extracted from
frozen hippocampal and cortical tissue using the RNeasy
kit (Qiagen). Reverse transcription was performed using a
High-Capacity cDNA Reverse Transcription kit (Life
Technologies). Real-time qPCR was conducted with Taq-
Man primers (Life Technologies) and the TaqMan
Universal PCR Master Mix (Life Technologies) using an
ABI Prizm 7500 Thermocycler. Relative gene expression
levels in NMNAT3 Tg and NMNAT3 WT mice in differ-
ent brain regions were compared using the DDCt method
with 18S mRNA as a control reference.
NMNAT3 knockdown and NMNAT3
overexpression using adeno-associated viral
vectors
Five candidate mouse shNMNAT3 clones were initially
obtained (McDonnell Genome Institute, Washington
University, St. Louis, MO) and introduced into HeLa cells
utilizing lipofectamine-mediated transfection. We then
identified a shNMNAT3 clone capable of reducing
endogenous NMNAT3 mRNA levels in these cells by
approximately 90% (88  9%). This shRNA was also able
to decrease the NMNAT3 mRNA levels of wild-type non-
infected and AAV8-mediated NMNAT3 overexpressing
neurons by approximately 40% (Fig. 6A and B). The can-
didate shNMNAT3 construct (NM_144533.1-870s1c1)
was then engineered into a serotype 8 adeno-associated
viral vector (AAV8) under the control of a U6 promoter
also containing a CMV-GFP reporter (Washington
University Viral Core, St. Louis, MO). AAV serotype 8
vector was chosen due to its high tropism toward neu-
rons. For all viral experiments, cells were exposed to
7.1E + 9 vg/lL of AAV8-shNMNAT3 virus or AAV8-
shScramble control (unless otherwise specified) until the
cells and cultured media were examined or the cells sub-
jected to the excitotoxic death assay as described above.
For exogenous NMNAT3 overexpression of dissociated
cortical and hippocampal neurons, an AAV8 virus was
produced containing the human sequence of NMNAT3
(MIM:608702; Location 3q23) under the regulation of the
neuron-specific synapsin-1 promoter. This vector when
used at a concentration of 8.3E10 + 9 vg/100 K cells was
found to increase neuronal NMNAT3 mRNA by
98  8.8-fold 6 days postinfection (Fig. 6A). Neurons
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were infected with the AAV8-syn1-NMNAT3-overexpres-
sing vector at a concentration of 8.3E10 + 9 vg/lL unless
otherwise specified.
Statistics
Data are presented as mean  SEM and were compared
using one-way ANOVA followed by Bonferroni test for
multiple comparisons, one-sample t-test for hypothetical
value comparisons, and one- or two-tailed Student’s t-test
for two-group comparisons. Statistical significance was set
at 0.05, where *P < 0.05, **P < 0.01, and ***P < 0.001.
Statistics were performed using GraphPad Prism (Graph-
Pad Software).
Results
Cerebral protein expression and localization
in NMNAT3 transgenic mice
In order to examine the neuroprotective properties of
NMNAT3 following neonatal brain injury, we utilized
NMNAT3-overexpressing transgenic mice (mouse line
#819) previously described to have decreased axonal
degeneration following sciatic nerve injury.15 We first
aimed at characterizing the cerebral localization of
NMNAT3 in the young postnatal mouse brain utilizing
conventional immunohistochemical and immunoblotting
methods. Compared to wild-type animals, NMNAT3
immunoreactivity (IR) of NMNAT3-overexpressing trans-
genic mice (NMNAT3-Tg) is highly abundant being pre-
dominantly found in the hippocampus and cerebral
cortex (Fig. 1A). NMNAT3-IR was mainly neuronal as
noted by its primary presence in NeuN+ neurons
(Fig. 1B). NMNAT3-IR was also found to a much lesser
extent in the hippocampal regions of high neurite density
indicating that NMNAT3 is partially and differentially
distributed across the neuronal axis that include the cyto-
plasm of the cell body and its projections (Fig. 1C and
D). Furthermore, NMNAT3 immunofluorescence in the
NMNAT3-Tg mouse brain appeared in a punctate-like
manner in the cell body and its processes (Fig. 1B and D)
consistent with the prior observation demonstrating that
NMNAT3 is mainly localized to the mitochondrial com-
partment in these mice.15
Endogenous cerebral NMNAT3 is induced by
neonatal cerebral hypoxia-ischemia
Previous research and our own aforementioned observa-
tions suggest that endogenous NMNAT3 is expressed at
relatively low baseline levels in the wild-type rodent
brain,5,7,8 although recent evidence supports the notion
that its CNS abundance may be region specific given that
it has been substantially localized to the cytoplasm of
mouse retinal neurons and their optic nerve fibers.9 Fur-
thermore, endogenous NMNAT levels are known to
increase in response to cellular stress including hypoxia
indicating that NMNAT proteins are potentially adaptive
molecules that may provide neuroprotective actions in
response to brain injury.20,21 Therefore, we investigated
whether endogenous NMNAT3 levels in the immature
mouse brain are affected by in vivo cerebral hypoxia and/
or ischemia. To examine this question, we measured
endogenous NMNAT3 expression in hippocampal and
cortical tissue from C57BL/6 neonatal na€ıve and injured
mouse brains 24 h, 72 h, and 7 days after neonatal H-I
(Fig. 2) utilizing the modified Levine method of neonatal
brain injury at postnatal day 7 (unilateral carotid ligation
followed by 45 min of 8% oxygen hypoxia). NMNAT3
mRNA and relative protein expression was then examined
by conventional quantitative PCR and immunoblotting
techniques. Mouse cortical and hippocampal NMNAT3
mRNA levels increased during the first 72 h following
injury in both, the hypoxic and hypoxic-ischemic side of
the brain when compared to age-matched na€ıve control
tissue (Fig. 2A). NMNAT3 mRNA returned to baseline
levels when examined 7 days after neonatal H-I suggesting
that NMNAT3 is upregulated in response to cerebral
hypoxia and/or ischemia in a postinjury time-dependent
manner. Similarly, while NMNAT3 immunoreactivity by
Western blot was consistently absent in the na€ıve unin-
jured neonatal mouse, we observed a measurable increase
in NMNAT3 protein levels in the neonatal hypoxic and
ischemic hippocampus when examined 24 h after neona-
tal H-I (Fig. 2B). Taken together, the above observations
suggest that endogenous NMNAT3 is induced in vivo
during the acute injury phase of neonatal cerebral
hypoxia and ischemia.
NMNAT3 protects the immature
hippocampus from the effects of neonatal
cerebral hypoxia-ischemia
Having established that NMNAT3 Tg mice demonstrate
high levels of NMNAT3 in brain regions commonly
affected following newborn cerebral hypoxia-ischemia, we
then examined whether NMNAT3 overexpression
decreases total cerebral tissue injury following neonatal
cerebral H-I. We first tested this hypothesis by subjecting
human term-equivalent (P7) NMNAT3 Tg mice and WT
littermates to the modified Levine brain injury technique
utilizing 45 min of 8% hypoxia and then examining hip-
pocampal, striatal, and cortical tissue injury 7 days after
neonatal H-I. Utilizing this length of hypoxia, we first
observed that total NMNAT3 Tg pup mortality during or
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Figure 1. Immunohistochemical localization of NMNAT3 in the young NMNAT3-overexpressing postnatal brain. (A) NMNAT3 DAB
immunohistochemistry of representative brain coronal sections from a NMNAT3 wild-type (NMNAT3-WT) and NMNAT3-overexpressing transgenic
(NMNAT3-Tg) mouse brain at postnatal day 14. (B–D) Composite digital micrographs of NMNAT3 fluorescence immunoreactivity (NMNAT3-IR) in
the postnatal NMNAT3-Tg hippocampus. NMNAT3-IR is primarily found colocalized to neurons and regions of enriched neuronal processes as
demonstrated by double immunofluorescence of NMNAT3 with neuronal antigen (B; NeuN) and neurofilament 200 (C and D; NF-200). Scale
bar = 110 lm (B), 440 lm (C), and 100 lm (D).
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right after hypoxic-chamber exposure was reduced by half
compared to that of WT littermates (Fig. 3A). Examina-
tion of the surviving mice brain tissue 7 days after H-I
demonstrated that animals with NMNAT3 overexpression
had decreased cortical tissue injury and a trend toward a
decrease in hippocampal neurodegeneration (Fig. 3A).
Given that total mortality was higher in WT compared to
NMNAT3 Tg mice prior to tissue injury quantification,
we reasoned that the lack of statistical significance in the
hippocampal measurements might be attributed to a
selection bias toward less severely injured WT mice
brains. To eliminate this confounder, we repeated the
experiment while lowering the period of 8% hypoxia to
15 min. Utilizing this approach, pup mortality during or
immediately after hypoxia was absent in the WT and
NMNAT3 Tg group. Furthermore, NMNAT3 overexpres-
sion decreased hippocampal tissue injury by 56% when
compared to WT mice littermates when examined 7 days
post-H-I (Fig. 3B). These observations suggest that
NMNAT3 reduces the acute effects of cerebral hypoxia
and ischemia, while it also protects the neonatal cerebral
cortex and hippocampus against the neurodegenerative
effects of neonatal H-I.
NMNAT3 decreases neuronal degeneration
in the injured neonatal brain via a caspase/
calpain-mediated pathway
In order to understand the cellular mechanisms involved
in NMNAT3-dependent neuroprotection, we examined
whether NMNAT3 overexpression affects the activity of
calpain and caspase-3 in the neonatal hippocampus fol-
lowing H-I-utilizing immunoblotting and caspase-3 enzy-
matic assays. Calpain and caspase-3 are cysteine proteases
essential for the activation of necrotic and apoptotic neu-
rodegeneration as a result of neonatal H-I.1,16,22,23 The
cytoskeletal protein, spectrin, is cleaved by both caspase-3
and calpain resulting in 120 KDa fragment reflecting cas-
pase cleavage and a 145 and 150 KDa fragment represent-
ing calpain cleavage when assessed using SDS-PAGE.23
Figure 2. Endogenous NMNAT3 is induced by neonatal cerebral hypoxia and ischemia. (A) Bar graphs demonstrating the relative increase in
NMNAT3 mRNA (from noninjured age-matched controls) in the neonatal hypoxic (nonligated side) and hypoxic-ischemic (H-I) cerebral cortex (Cx)
and hippocampus (Hp) 1, 3, and 7 days after injury at postnatal day 7 (number inside bar equals # of animals per condition). (B) NMNAT3 Western
blot immunoreactivity (IR) of the neonatal hippocampus (Hp) from noninjured NMNAT3-Tg (Tg) and wild-type (WT) animals, and from WT
hippocampi examined 24 h post-H-I. We consistently observed no NMNAT3 IR in control hippocampi. However, NMNAT3 immunoreactivity was
notably present following injury in the hypoxic (Hypoxic Hp) and hypoxic-ischemic hippocampus (H-I Hp). Bar graph represents the relative
quantitative density of the blots shown from the injured hippocampi relative to noninjured brains (N = 5). * p < 0.05; ** p < 0.01; *** p < 0.001
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Caspase-3 activity is marker of neuronal apoptosis,22
while calpain cleavage of spectrin after neonatal H-I is
caspase-3 independent and thus serves as a measure of
nonapoptotic cell death.16 Neonatal hippocampal lysates
from control, WT littermates evaluated 24 h post-H-I
(carotid ligation followed by 45 min of hypoxia) revealed
markedly increased levels of both caspase- and calpain-
specific spectrin cleavage products in the ipsilateral
ligated, injured, side when compared to the contralateral,
uninjured, hippocampus (Fig. 4A–D; WT). In contrast,
the calpain and caspase cleavage products of NMNAT3-
overexpressing mice were markedly decreased in the
injured hippocampus (Fig. 4A–D; N3). Furthermore,
NMNAT3-overexpressing mice showed no statistical dif-
ferences in calpain and caspase cleavage products between
their injured and uninjured hemispheres (Fig. 4A–D). To
further corroborate the above findings, we examined the
enzymatic activity of capase-3 in injured hippocampal
lysates of NMNAT3 Tg and WT mice 24 h post-H-I.
Congruent with our spectrin results, NMNAT3 overex-
pression resulted in a decrease in hippocampal caspase-3
activation (Fig. 4E). These results suggest that NMNAT3
protects the neonatal hippocampus against the neurode-
generative effects of H-I via a mechanism involving the
inhibition of key proteins associated with both neuronal
necrosis and apoptosis.
The neuroprotective effects of NMNAT3
after neonatal cerebral injury are associated
with a decrease in the calpain-specific
protease, calpastatin
In order to further explore the mechanism of NMNAT3-
mediated calpain/caspase inhibition, we examined the
contribution of calpastatin degradation on NMNAT3-
dependent neuroprotection following neonatal H-I. Cal-
pastatin (CASTN) is a calcium-activated cysteine protease
responsible for the proteolytic inhibition of calpains.23,24
Increases in intracellular calcium after neonatal cerebral
ischemia lead to the activation of calpains and subsequent
degradation of CASTN resulting in unopposed activation
of calpain-mediated neuronal cell death.25–27 Caspase-3
also promotes the degradation of CASTN in early apop-
totic neurodegeneration. This effect allows further com-
promise of the neuronal cell membrane causing further
increases in cytoplasmic calcium and calpain activation.23
Indeed, CASTN appears to be a key suicide substrate for
the degeneration of neurons as a result of ischemic cere-
bral injury.25 Furthermore, CASTN has been recently
implicated in the inhibition of axonal degeneration by
NMNATs as overexpression of cytoplasmic NMNAT1
from injured axons of dorsal root ganglia (DRG) pre-
vented injury-induced CASTN degradation in vitro.28
Figure 3. NMNAT3 overexpression reduces cortical and hippocampal
tissue loss following neonatal H-I. (A) Relative tissue loss (calculated
by the percent difference between left (L) ipsilateral, ischemic, and
right (R) contralateral, nonischemic, hemisphere) in the hippocampus
(Hp), striatum (Str), and cerebral cortex (Cx) 7 days after carotid
ligation followed by 45 min of hypoxia. Right bar graph shows total
mortality during or immediately after 45 min of hypoxia chamber in
wild-type (WT) and NMNAT3 transgenic (Tg) mice. (B) Relative tissue
loss 7 days post-H-I using 15 min of hypoxia chamber exposure, a
paradigm with zero hypoxia-induce mortality. (C) Representative
coronal digital micrographs taken from injured WT and NMNAT3 Tg
animals with 15 min of global hypoxia. * p < 0.05
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Therefore, we investigated whether NMNAT3 overexpres-
sion results in the inhibition of CASTN degradation after
neonatal H-I. Relative CASTN levels were measured by
SDS-PAGE followed by Western blotting from neonatal
P7 hippocampi of NMNAT3-overexpressing and WT
mice 24 h after H-I. Consistent with our calpain and cas-
pase findings, CASTN levels were significantly reduced in
the ipsilateral, injured hippocampus of WT animals com-
pared to the contralateral, injured, side (Fig. 5A and B).
In contrast, NMNAT3 overexpression decreased injury-
mediated CASTN degradation of the neonatal hippocam-
pus (Fig. 5A and B). These data further implicate CASTN
as a likely important mechanistic target involved in
Figure 4. NMNAT3 overexpression reduced the activation of calpain
and caspase-3 following neonatal H-I in neonatal hippocampus.
Quantitation (A, B, and D) and representative blot (C) of the relative
immunoreactive band density by the corresponding spectrin
breakdown product (SBPD; 145 and 150 kDa cleaved by calpain,
120 KDa cleaved by caspase) from wild-type (WT) and NMNAT3-
overexpressing transgenic (N3) mice in the right (R) uninjured,
nonischemic, versus left (L) injured, ischemic, hippocampus 24 h after
H-I. (E). Quantitation of caspase-3 activity in WT and N3 transgenic
mice of the injured and uninjured side measured 24 h after neonatal
H-I. N = 8 animals per group. * p < 0.05; ** p < 0.01; *** p < 0.001
Figure 5. NMNAT3 overexpression decreases the degradation of
calpastatin following H-I. Quantitation (A) and representative blot (B)
of the relative calpastatin (CASTN) total band immunoreactive density
by Western blot from wild-type (WT) and NMNAT3-overexpressing
transgenic (N3) mice in the right (R) uninjured, nonischemic, versus
left (L) injured, ischemic, hippocampus 24 h after H-I (N = 8/group).
** p < 0.01; *** p < 0.001
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NMNAT3-mediated neuroprotection from the effects of
neonatal H-I.
Alterations in NMNAT3 expression in vitro
affect baseline neuronal survival and
glutamate-dependent excitotoxicity
Lastly, we wanted to investigate whether alterations in
endogenous and exogenous NMNAT3 expression in vitro
affect the survival of nontransgenic mouse hippocampal
and cortical neurons under basal and injurious conditions.
To examine the effect of endogenous NMNAT3, we
infected E18 embryonic dissociated cortical and hippocam-
pal neurons on DIV3 with an AAV8 mouse shNMNAT3
knockdown viral vector containing a Green Fluorescent
Protein (GFP) reporter. A shRNA scrambled AAV8 vector
was used as a control for all viral experiments and in vitro
neuronal injury assays. Neuronal infection as assessed by
GFP reporter immunofluorescence cytochemistry was pre-
sent in nearly all neurons by 3 days following viral expo-
sure (Fig. 6C). Utilizing LDH levels as a relative
quantitative measure of neuronal viability, we observed a
significant increase in LDH activity as early as 6 days post-
AAV8-shNMNAT3 exposure in both cortical (Fig. 7A;
shN3) and hippocampal neurons (Fig. 8A; shN3). This
increase was associated with visual qualitative fragmenta-
tion of GFP-positive neurites, and a quantitative decrease
in MAP2 immunofluorescence in these two neuronal pop-
ulations indicating that in vitro shNMNAT3 exposure
increases the degeneration of neuronal processes (Fig. 7C
and D and 8C and D; shN3). Five-minute exposure to the
glutamate-agonist, ibotenic acid (50 lmol/L), resulted in
further increases in cell death in neurons infected with the
shNMNAT3 viral vector as compared to shScramble con-
trol when examined 24 h following transient excitotoxic
agent administration (gray bars Figs. 7A and 8A;
shN3 + IBO). Furthermore, shNMNAT3 vector exposure
decreased endogenous mouse NMNAT3 mRNA levels by
40% without affecting the levels of NMNAT1 and
NMNAT2 indicating that this effect is not caused by a
decrease in the expression of the other, more abundant,
NMNAT isoforms (Fig. 6B). The above observations sug-
gest that endogenous NMNAT3 mRNA downregulation
decreases baseline neuronal survival, and that this effect is
further potentiated by glutamate-mediate excitotoxicity.
We then asked whether AAV8-shNMNAT3-mediated
neuronal degeneration can be rescued by NMNAT3
overexpression. To answer this question, we examined
neuronal viability and neurite density in neurons
exposed to a NMNAT3-overexpressing vector capable of
increasing NMNAT3 by 100-fold in the presence or
absence of the shNMNAT3 vector (Fig. 6A; Viral N3).
The AAV8-NMNAT3-overexpressing vector contained a
neuron-specific synapsin-1 promoter to investigate these
effects exclusively in neurons. Exposure to the
NMNAT3-overexpressing vector was divided into four
groups and all exposures began at DIV5 and were
assessed at DIV13: (1) neurons exposed to NMNAT3-
overexpressing vector only (N3 only; 8.3E + 9 vg/well);
(2) neurons exposed simultaneously to nearly equal
concentrations of shNMNAT3 (shN3; 7.1E +9 vg/well)
and NMNAT3-overexpressing vector (N3; 8.3E + 9 vg/
well); (3) neurons exposed to shN3 3 days PRIOR to
Figure 6. AAV8 shRNA-mediated GFP expression and relative gene
expression of NMNATs in na€ıve, noninfected, and shNMNAT3 and/or
human NMNAT3-infected cortical neurons. (A) Quantitative amount
of endogenous mouse NMNAT3 mRNA (Endog. N3; N = 4) versus
viral-transduced NMNAT3 mRNA in the presence (N = 3) or absence
(N = 4) of AAV8-mouse shNMNAT3 knockdown vector for 6 days. (B)
Effect of AAV8-mouse shNMNAT3 knockdown vector exposure on
endogenous mRNA levels of mouse NMNAT1 (mN1), NMNAT2 (mN2),
and NMNAT3 (mN3) in cortical neurons (N = 4 animals; each value
calculated as average mRNA of three culture wells/animal/condition;
negative value represents decrease from baseline). (C) Representative
low-power (bar = 440 lm) and high-power (squared inserts;
bar = 55 lm) single and composite micrographs of cultured cortical
neurons stained for neuronal antigen (NeuN) 3 days after AAV8-
shNMNAT3-GFP or AAV8-shScramble-GFP vector exposure. AAV8-
shNMNAT3 and shScramble vector expression is present in the
majority of neurons and their processes by 3 days postinfection as
assessed by GFP fluorescence. * p < 0.05; ** p < 0.01; *** p < 0.001
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Figure 7. NMNAT3 mRNA depletion increases markers of neuronal cell death and enhances glutamate-dependent excitotoxic degeneration of
cortical neurons in vitro. The prodegenerative effect of NMNAT3 mRNA knockdown is reduced by NMNAT3 overexpression. (A) Effect of
endogenous NMNAT3 knockdown on LDH activity in cortical neuronal cultures exposed to AAV8-shNMNAT3-GFP (shN3) virus for 6 days prior
(N = 6) and 24 h (N = 4) after 50 lmol/L ibotenic acid exposure (shN3 + IBO), or exposed to a human NMNAT3-overexpressing vector alone (N3;
N = 6). The percent change in LDH activity was calculated as the change in LDH activity from that of experimentally paired neurons exposed to
control AAV8-shScramble vector for 6 days prior and 24 h after IBO exposure. Notice the significant elevation in LDH activity in shN3-exposed
neurons above shScramble control at baseline and following IBO exposure. LDH activity in N3-exposed neuronal cultures appeared to be mildly
reduced compared to shScramble controls. (B and C) Percent change in baseline LDH activity compared to shScramble controls (B) and amount of
MAP2 immunoreactivity per unit area (C) 9 days postinfection with the mouse NMNAT3 knockdown AAV8 (shN3) in the presence (N = 4/group)
or absence (N = 12/group) of the human NMNAT3-overexpressing vector at the time (shN3 + N3), 3 days prior (N3 then shN3), or 3 days after
(shN3 then N3) shN3 viral vector exposure. (D) Representative micrographs of shNMNAT3 GFP-positive neurons alone (high-power; bar = 110 lm)
or stained with MAP2 (low-power; bar = 1100 lm) and infected with the shN3 vector with or without N3-overexpressing virus. GFP
fragmentation, increased visualization of morphologically appearing astrocytes (see GFP-shN3 panel), and a decrease in MAP2 + neurite staining
was found primarily in shN3-exposed neurons. The presence of the N3-overexpressing vector in shN3-treated neurons did not decrease, but rather
qualitatively increase, shNMNAT3 GFP-positive fluorescence.* p < 0.05; ** p < 0.01; *** p < 0.001
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N3-vector exposure; and (4) neurons infected with
shN3 3 days AFTER N3-vector exposure. Findings were
then simultaneously compared to neurons only exposed
to the AAV8-shScramble control virus (shScramble;
7.1E + 9 vg/well). Concomitant exposure of the N3-
overexpressing vector did not appear to negatively affect
shNMNAT3 knockdown virus infection as the degree of
GFP fluorescence generated by the shNMNAT3 vector
did not appear to decrease in its presence (Fig. 7D).
Cortical neurons exposed to the shN3 vector
concomitantly with the N3 vector or infected with
shN3 3 days after N3 vector exposure demonstrated sig-
nificant improvement in shN3-mediated neuronal viabil-
ity as assessed by decreases in LDH activity 8 days
postviral infection (Fig. 7B and D). N3 vector exposure
alone did not negatively affect neuronal survival or
neurite density when compared to shScramble control
(Fig. 7B and C). In fact, N3-only exposed cortical and
hippocampal neurons had significantly lower baseline
LDH activity levels when compared to the viral vector
control-infected neurons suggesting a healthier baseline
status (Figs. 7A and 8A; N3). Furthermore, shN3-
mediated neurite degeneration as assessed by the
amount of MAP2 immunofluorescence was significantly
decreased in the presence of N3-overexpressing vector
irrespective of the timing of shN3 exposure (Fig. 7C
and D). A similar effect was also observed in hip-
pocampal neurons (Fig. 8C and D). Taken together, the
above data suggest that upregulation of NMNAT3
expression protects neurons against the prodegenerative
effects of NMNAT3 mRNA depletion.
Discussion
In this study, we asked whether NMNAT3 protects the
immature mouse brain from the effects of cerebral hypox-
ia-ischemia. We find that increases in cerebral NMNAT3
decrease total hippocampal and cortical injury following
neonatal H-I. This effect is associated with a decrease in
calpain and caspase-3 activity and a decrease in the
injury-mediated degradation of calpastatin. In addition,
decreases in baseline endogenous NMNAT3 mRNA
in vitro increased neuronal degeneration and enhanced
glutamate-dependent excitotoxicity, an injury mechanism
thought to be important in the pathogenesis of perinatal
cerebral injury. The neurotoxic effect observed from
NMNAT3 knockdown in vitro and its near complete
reversal by exogenous upregulation of NMNAT3 further
supports the notion that NMNAT3 is important for
maintaining the viability of developing neurons. To our
knowledge, this is the first report demonstrating the neu-
roprotective actions of a natively found non-nuclear
NMNAT in the neonatal injured brain. These observa-
tions also strengthen the increasing body of literature
demonstrating the importance of NMNATs in promoting
neuronal and axonal survival not only of the peripheral
but also of the central nervous system.
Neuroprotective role of NMNAT3 in injured
developing neurons
The result demonstrating that NMNAT3 overexpression
decreased hippocampal and cortical degeneration
Figure 8. NMNAT3 mRNA knockdown also decreases hippocampal
neuronal survival markers, an effect that is partially reversed by
NMNAT3 upregulation. (A) Percent change in LDH activity compared
to AAV8-shScramble-GFP viral control in hippocampal neurons
infected with AAV8-human NMNAT3 (N3; N = 6) or AAV8-
shNMNAT3-GFP (shN3) virus for 6 days prior (N = 6) or 24 h (N = 4)
after 50 lmol/L ibotenic acid exposure (IBO). Similar to the effect seen
in cortical neurons, shN3 viral vector exposure increased LDH activity
above control neuronal cultures prior and after injury with IBO. (B and
C) Percent change in baseline LDH (B) and amount of MAP2
immunoreactivity per unit area (C) 9 days postneuronal infection with
the mouse shN3 vector alone or 3 days after human N3
overexpressing vector (N3 then shN3; N = 6/group). (D) Representative
micrographs of shNMNAT3-GFP-positive neurons (high-power;
bar = 110 lm) or stained with MAP2 (low-power; bar = 1100 lm)
and infected with the shN3 vector 3 days after N3-overexpressing
vector exposure. * p < 0.05; ** p < 0.01; *** p < 0.001
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following neonatal H-I is supported by previous observa-
tions showing similar neuroprotective effects in other
neural tissues and species.9,15,29–31 In vivo increases in
rodent NMNAT3 prevented the degeneration of injured
axons of central olfactory receptor neurons in the Droso-
phila brain and of retinal ganglion neurons of the rat
eye.9,29,30 Similarly, NMNAT3 overexpression conferred
strong neuroprotection against axonal degeneration of the
mouse injured sciatic nerve in vivo and of damaged DRG
axons in vitro.15,30,31 Furthermore, our observation that
NMNAT3 reduced cerebral tissue loss in the hippocam-
pus and cerebral cortex suggests that the extent of the
neuroprotective actions of NMNATs may be dependent
on their anatomical and cellular expression as well as
mode of injury. Indeed, immunohistochemical localiza-
tion of cerebral NMNAT3 appeared to be primarily pre-
sent in neuronal cell bodies of the cerebral cortex and
hippocampus (Fig. 1), and previous research has shown
that overexpression of cytoplasmic NMNAT1 following
neonatal cerebral H-I resulted in a more global protective
effect similar to the one found with NMNAT3 in this
study.11 In addition, we find that endogenous NMNAT3
levels are increased during the first 72 h following neona-
tal H-I. This effect is congruent with previous observa-
tions demonstrating that NMNATs are inducible under
conditions of anoxic cellular stress.21,32 Drosophila brain
NMNAT levels are upregulated following hypoxia via a
mechanism involving the activation of hypoxia-inducible
factor alpha (HIFa) and heat shock factor.21 Interestingly,
NMNAT1 and HIFa peripheral blood mRNA levels are
also increased in people living at high altitudes suggesting
that the expression of HIFa and NMNATs is also adaptive
to low oxygen conditions in humans.33,34 Moreover, HIFa
is a transcription factor importantly involved in the regu-
lation of neuronal survival of injured neurons following
neonatal H-I and it is also actively upregulated in
response to repeated neonatal cerebral hypoxia.35 There-
fore, increases in the endogenous expression of NMNAT3
in response to neonatal cerebral hypoxia and ischemia
may represent an internal mechanism by which the
immature neuron attempts to protect itself from the
degenerative effects brought on by excessive metabolic
stress. This hypothesis is supported by the observation
that NMNAT3 upregulation in the fly brain is capable of
enhancing the life span of flies in response to oxidative
stress.21 Similarly, NMNAT3 overexpression reduced the
degeneration of DRG axons after exposure to exogenous
toxic oxidants such as rotenone and hydrogen peroxide,30
and increases in Drosophila NMNAT prevented hypoxia-
induced degeneration of neuronal dendrites.20,36 In this
study, we also find that NMNAT3-overexpressing mice
have lower mortality during the acute phase of H-I com-
pared to their littermate controls (Fig. 3A). The decreased
mortality during and/or immediately following
hypoxia-ischemia in the NMNAT3-overexpressing mice
was an unexpected and interesting finding that likely
needs future study. In addition to their aforementioned
role in oxidative stress, NMNAT targeted to mitochondria
have been shown to facilitate mitochondrial calcium
buffering capacity.37 Mitochondrial dysfunction is well
known to affect neuronal excitability through its role in
calcium buffering, neurotransmitter biosynthesis, and
redox homeostasis.38 It is thus possible that chronic
increases in NMNAT3 expression, such as those seen in
NMNAT3 transgenic mice, may contribute to an amelio-
ration in neuronal excitability during excessive neuronal
stress and may in turn decrease the risk for death during
the acute phase of H-I.
Our results showing significant increases in cortical and
hippocampal neurodegeneration after NMNAT3 mRNA
downregulation and its subsequent rescue by exogenous
human NMNAT3 (Figs. 7–8) further support the afore-
mentioned increasing scientific evidence that endogenous
NMNATs are likely important for maintaining neuronal
survival. These findings are rather surprising given the
relatively low expression of NMNAT3 in the immature
brain. Our observation also contrasts previous research
demonstrating that injection of NMNAT2 but not
NMNAT3 siRNA to superior cervical ganglion neurons
caused neurite degeneration when examined 72 h post-
transfection.39 These differences may be attributed to the
timing of observation, type of neuron, and duration of
siRNA exposure, given that neuronal degeneration and
processes fragmentation in our cultures were not observed
until 6 days postinfection, and viral-mediated transduc-
tion of shRNA produces a more wide spread and long-
lasting level of siRNA expression when compared to
direct siRNA injection.40 Although we cannot conclusively
exclude the possibility that neuronal exposure and infec-
tion with our shNMNAT3 viral vector negatively affect
other survival genes, we did not observe changes in the
endogenous expression of NMNAT1 and NMNAT2
(Fig. 6B). Additionally, exposure to the control shScram-
ble vector did not affect neuronal survival (Figs. 7–8). Of
note, NMNAT3 knockout mice appear viable,41 although
it is not yet known whether these mice have abnormalities
in neuronal development or survival under basal or inju-
rious conditions. Lastly, increases in endogenous
NMNAT3 24 h following H-I were primarily observed in
the hypoxic side of the pup brain. Although NMNAT3
protein levels were relatively increased in the ischemic
hippocampus, we did not observe a corresponding eleva-
tion in NMNAT3 mRNA in this region (Fig. 2). In our
injury model, the hippocampus undergoes the most sev-
ere injury and it is possible that the mechanism of
NMNAT3 induction is partially overwhelmed and/or
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delayed by the extent of injury. This may be the reason
why the highest increases in mRNA and NMNAT3 Wes-
tern blot immunoreactivity were observed in the hypoxic-
only tissues or the ischemic cerebral cortex, a brain region
that undergoes a relatively lesser degree of injury. Future
studies should aim at characterizing further the differen-
tial expression and cellular compartmentalization of
NMNATs in the developing brain while further exploring
the mechanisms responsible for NMNAT induction. The
above likely will provide a better understanding of the
regional, environmental, and internal cellular triggers that
modulate neuronal NMNAT expression and NMNAT-
mediated neuronal survival.
Taken together, our observations indicate that endoge-
nous and exogenous NMNAT3 is neuroprotective against
the effects of neonatal brain injury. Furthermore, studying
the mechanisms and cellular triggers that modulate the
endogenous expression of NMNATs is of translational
importance as exploring biological strategies targeted at
increasing the levels of these proteins in brain may prove
beneficial against disease conditions of compromised neu-
ronal health.
Role of mitochondria in NMNAT3-mediated
neuroprotection
Numerous studies have demonstrated that NMNAT3 is
likely the primary NMNAT isoform present in mitochon-
dria,6,7,9,15,42–46 and our observations and those of previ-
ous reports suggest that NMNAT3 in NMNAT3-Tg mice
is also primarily localized to this organelle.15,31 Mitochon-
dria play an essential role in neuronal survival following
cerebral injury and recent findings suggest that mitochon-
dria are important cellular compartments involved in the
neuroprotective actions of NMNATs.37,47 For example,
and as mentioned above, NMNAT targeted to the mito-
chondria enhanced mitochondrial calcium buffering, and
reduced axotomy-induced calcium elevation and Walle-
rian degeneration of mouse Drosophila axons.37 Further-
more, genetic elimination of axonal mitochondria in
Drosophila prevented NMNAT’s ability to reduce Walle-
rian degeneration of injured neuronal fibers.47 In contrast,
increases in NMNAT3 expression enhanced the ATP syn-
thetic activity of mitochondria and reduced axonal degen-
eration following mouse sciatic nerve injury.15 Therefore,
NMNAT3 is likely important in maintaining neuronal
integrity during disease conditions that alter mitochon-
dria-associated ATP metabolism and calcium homeostasis
such as during and after neonatal H-I. If NMNAT3 pro-
tects neurons against neonatal hypoxic-ischemic neurode-
generation via a pathway that involves alterations in
mitochondrial bioenergetics and mitochondrial-mediated
calcium buffering, one is expected to find NMNAT3-
mediated decreases in the function of death-promoting
cellular substrates activated as a result of this organelle’s
dysfunction. In support of this hypothesis, we find that
NMNAT3 overexpression following neonatal H-I
decreased the activity of calpain and caspase-3 (Fig. 4),
two proteases that are well known to be triggered by the
cellular events that lead to the permeabilization and
altered function of mitochondria in ischemic neurons.48,49
Furthermore, we also observed that NMNAT3 upregula-
tion was associated with a significant decrease in the
degradation of calpastatin (Fig. 5), a calcium-sensitive
protease known to inhibit the activity of both calpains
and caspase-3.23–27 It is thus tempting to suggest that the
biological mechanism by which NMNAT3 protects neu-
rons against the effects of neonatal H-I involves an
increase in the capacity of mitochondria to buffer the
rapid increases in intracellular calcium as a result of
ischemia-induced glutamate-dependent excitotoxicity,
thereby preventing calpastatin degradation and the subse-
quent activation of calpain and caspase-3. This is sup-
ported by our in vitro observation showing a substantial
increase in cortical and hippocampal neuronal degenera-
tion upon NMNAT3 mRNA depletion 24 h following
glutamate receptor agonist administration (Figs. 7A, 8A).
Therefore, future research efforts may aim at characteriz-
ing the specific signaling mechanisms that link NMNATs
and calcium-activated death-modulating proteins such as
calpastatin. Notably, although our observations agree with
previously published work indicating that NMNATs are
important enzymes for the regulation of neuronal degen-
eration, our experiments do not directly assess the specific
sequence of biochemical events that lead to NMNAT3-
mediated neuroprotection following neonatal hypoxia-
ischemia, an important subject that needs future study.
Yet, published observations suggest that the calpastatin-
calpain pathway is a likely common downstream cellular
mechanism involved in NMNAT-mediated neurodegener-
ation. For example, injured axons of dorsal root ganglia
neurons transfected with mutant cytoplasmic NMNAT1
prevented axotomy-induced calpastatin degradation, while
knockdown of calpastatin accelerated the degeneration of
injured neuronal fibers.15 More recent evidence indicates
that NMNAT2 inhibits the depletion of ATP triggered by
the activation of sterile alpha and Toll/interleukin-1
receptor motif-containing protein-1 (SARM1) following
axotomy, a prodegenerative NADase involved in axonal
degeneration.50,51 Interestingly, calpain inhibition or cal-
pastatin overexpression did not prevent the energy deple-
tion observed after axotomy.52 Taken together these
observations suggest that NMNATs functions upstream to
the cellular cascade that triggers the depletion of ATP and
subsequent activation of the calpain-calpastatin degenera-
tive cascade following axotomy. Although we cannot
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conclude that this same mechanism occurs in injured
immature brain neurons in response to increases in
NMNAT3, the above findings and the observation that
similar results have been noted in developing injured reti-
nal ganglion neurons28 suggest that NMNATs may
involve common death signaling pathways in both, the
peripheral and central nervous system. Yet, the various
NMNAT isoforms may individually differ in the cellular
mechanisms that they employ to protect the injured
brain. For example, in this work we found that NMNAT3
overexpression following H-I decreased caspase-3 activa-
tion, whereas this apoptotic enzyme appeared not to be
affected following HI in neonatal mice expressing high
levels of cytoplasmic NMNAT1.11 These differences fur-
ther contribute to newer evidence showing that the neu-
roprotective effects of NMNATs are not exclusively
related to their NAD+ synthetic activity.53 For example,
recent studies show that NMNAT1 and NMNAT2
decreased axon degeneration by preventing the SARM1-
dependent depletion of NAD+.50,54 Interestingly, increases
in the expression of NMNAT prevented SARM1-depen-
dent NAD+ depletion without increasing NAD+ produc-
tion.54 In addition, NMNATs have been recently shown
to have chaperon function in animal models of tau-
pathies.40,55 The above findings suggest that NMNATs
have a broader and more complex neuroprotective func-
tion and therefore, targeting the mechanisms that affect
the endogenous expression of these proteins may offer
novel and more wide spread neurotherapeutic
approaches.
Conclusions
NMNAT3 overexpression protects the term-equivalent
neonatal mouse hippocampus and cortex from the
degenerative effects of cerebral H-I. Cerebral hypoxia
and/or ischemia increases the expression of endogenous
NMNAT3. The neuroprotective effect of NMNAT3
involves a decrease in cerebral apoptotic and necrotic
degeneration possibly via a decrease in injury-related
calpastatin degradation and resultant inhibition of cal-
pain and caspase-3 activation. Endogenous NMNAT3 is
important for the survival of cortical and hippocampal
neurons in vitro under baseline and following glutamate
receptor-mediated excitotoxic injury, an effect that is
rescued by exogenous upregulation of NMNAT3. Our
results suggest that NMNAT3 is an important prosur-
vival molecule in the injured developing brain.
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